ADC Therapeutics released preliminary unaudited fourth quarter and full-year 2025 revenue estimations, with $22M and $73M respectively.
As of December 31, 2025, the company's cash and cash equivalents totaled approximately $261M, ensuring a secure cash runway until at least 2028.
Key catalysts for ADC Therapeutics include the completion of LOTIS-7 enrollment in the first half of 2026 and the expected release of LOTIS-5 Phase 3 topline data in the second quarter of 2026.
Financial Performance
ADC Therapeutics' preliminary net product revenue for 2025 reached $73M, marking growth from the previous year.
Cash Position
The company's cash and cash equivalents reached around $261M, providing financial stability until 2028.
Clinical Milestones
The anticipation of significant developments in the LOTIS-5 and LOTIS-7 trials signals potential future revenue acceleration.
- The stable demand for ZYNLONTA in the 3L/3L+ DLBCL indication reflects positive market response for ADC Therapeutics.
- Anticipated catalysts like the LOTIS-5 results and LOTIS-7 enrollment completion are expected to drive future growth potential and regulatory achievements.
The robust financial performance and ongoing clinical advancements position ADC Therapeutics for revenue growth and potential regulatory approvals in the upcoming years.